GREENWICH LIFESCIENCES INC. - COMMON STOCK

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

03 Apr 2025 07:00:09 By Nasdaq GlobeNewswire

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

02 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

27 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

17 Mar 2025 05:45:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 

10 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe 

29 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

27 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01 

23 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Provides Update on Commercial Manufacturing

22 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

14 Jan 2025 05:15:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France 

13 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Partners with GIM in Italy

26 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Provides Update on Corporate Events

18 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

01 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Set to Join Russell 2000 Index Again

26 Jun 2024 06:33:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Announces $2.5 Million Private Placement

14 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

13 Mar 2024 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

12 Mar 2024 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

27 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

22 Feb 2024 05:00:00 By Nasdaq GlobeNewswire